Theophylline for Treatment of Pseudohypoparathyroidism

Summary

Pseudohypoparathyroidism is a genetic disorder with limited treatment options, characterized by early-onset obesity, short stature, hormone resistance and cognitive impairment. This phase 2 clinical trial will test the efficacy of theophylline, a phosphodiesterase inhibitor, in pseudohypoparathyroidism. We hypothesize that theophylline will cause weight loss, improve glucose tolerance and decrease hormone resistance in children and young adults.

Timeline

Start

2020-05-22

Primary completion

2026-12-31

Completion

2026-12-31

Drugs

Indications